ENDRA Life Sciences
Corporate brand
UnclaimedENDRA Life Sciences is focused on early detection of liver disease using its TAEUS® technology.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
ENDRA Life Sciences is a company focused on early detection of liver disease. Its TAEUS® technology is a new, proprietary way to measure fat in the liver, CE-marked for sale in Europe. The technology is non-invasive and costs 50x less than MRI.
History
ENDRA Life Sciences is focused on early detection of liver disease. The company developed TAEUS® (Thermo-Acoustic Enhanced UltraSound), a technology that combines radio frequency and ultrasound waves to measure fat in the liver. TAEUS® is CE-marked and commercially available in Europe, and pairs with any B-mode ultrasound machine. The technology is non-invasive and costs 50x less than MRI.
Products and positioning
TAEUS®
TAEUS® is a new, proprietary way to measure fat in the liver that is now CE-marked for sale in Europe. It combines radio frequency and ultrasound waves to measure fat in the liver.
Recent events
Reported
ENDRA appoints Irina Pestrikova as Senior Director of Finance[4]
ENDRA Life Sciences announced Irina Pestrikova’s appointment as Senior Director of Finance and Principal Financial Officer. She will assume the day-to-day responsibilities previously performed by CFO David Wells.
Reported
ENDRA announces CFO David Wells’s departure[4]
ENDRA announced that CFO David Wells would leave the company effective June 18, 2021, to pursue another opportunity. He was to continue supporting ENDRA as a consultant through September 2021 to assist with the transition.
Reported
ENDRA Life Sciences reports first-quarter 2021 results[5]
ENDRA Life Sciences reported financial results for the three months ended March 31, 2021, including a net loss of $2.3 million.
ENDRA announces clinical study partnership with Inselspital University Hospital[6]
ENDRA Life Sciences announced a partnership with Inselspital University Hospital in Bern for a clinical study of ENDRA's TAEUS device to assess non-alcoholic fatty liver disease.
Reported
ENDRA Life Sciences announces pricing of public stock offering[7]
ENDRA Life Sciences announced pricing for an underwritten public offering of 7,143,000 common shares at $0.70 per share. The offering was expected to close on December 18, 2020, subject to customary closing conditions.
Reported
ENDRA and CHU Angers announce a clinical study partnership[8]
ENDRA Life Sciences announced that Centre Hospitalier Universitaire d'Angers is partnering with it on a clinical study evaluating ENDRA's TAEUS device for assessing NAFLD.
Reported
ENDRA announces clinical-study partnership with MCW[9]
ENDRA Life Sciences announced that the Medical College of Wisconsin was partnering with it on a clinical study of ENDRA's TAEUS device for assessing non-alcoholic fatty liver disease.
Reported
ENDRA and GE Healthcare renew collaboration agreement[10]
ENDRA Life Sciences announced that it renewed its collaboration agreement with GE Healthcare, extending the agreement's term to January 2021. GE Healthcare will continue supporting commercialization activities for ENDRA's TAEUS technology, while ENDRA will provide GE Healthcare certain rights of first offer related to manufacturing and licensing.
Sources11 sources
- 1Home - Endraendrainc.com
- 2About - Endraendrainc.com
- 3TAEUS - Endraendrainc.com
- 4ENDRA 任命 Irina Pestrikova 为高级财务总监finanznachrichten.de
- 5ENDRA Life Sciences公布2021年第一季度业绩finanznachrichten.de
- 6ENDRA宣布与Inselspital大学医院开展临床研究合作bostonstar.com
- 7ENDRA Life Sciences宣布公开发行普通股定价finanznachrichten.de
- 8ENDRA与昂热大学医院宣布临床研究合作finanznachrichten.de
- 9ENDRA宣布与威斯康星医学院开展临床研究合作finanznachrichten.de
- 10ENDRA与GE Healthcare续签合作协议finanznachrichten.de
- 11ENDRA Life Sciences Announces New Clinical Study Partnership with the Medical College of Wisconsin (MCW)finance.yahoo.com
Cite this profile: Cite the canonical profile. /brand-wiki/endra-life-sciences · Editorial policy · How profiles are compiled